表紙
市場調查報告書

肺部疾病藥物遞輸系統市場: 各產品類型、用途、地區 - 市場規模,佔有率,預測,及機會分析

Pulmonary Drug Delivery Systems Market, By Product Type, By Application, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 948391
出版日期 內容資訊 英文 178 Pages
商品交期: 2-3個工作天內
價格
肺部疾病藥物遞輸系統市場: 各產品類型、用途、地區 - 市場規模,佔有率,預測,及機會分析 Pulmonary Drug Delivery Systems Market, By Product Type, By Application, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年06月30日內容資訊: 英文 178 Pages
簡介

肺部疾病藥物遞輸系統,包含經口吸入、經鼻藥(OINDP),定量給藥(MDI),乾燥粉末吸入器(DPI),鼻噴霧,噴霧器等,全部的吸入產品,規定必須檢驗萃取物、浸出物、微生物污染物質。全球肺部疾病藥物遞輸系統市場在預測期間內的阻礙因素,是嚴格的法規與使用中的併發症。

本報告提供全球肺部疾病藥物遞輸系統市場的相關調查,市場機會和趨勢,成長及阻礙因素,各產品類型、用途、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 調查的目的與前提條件

第2章 市場展望

  • 報告概要
  • 市場定義和範圍
  • 摘要整理
  • 市場明細 : 各產品類型
  • 市場明細 :各用途
  • Coherent Opportunity Map (COM)

第3章 市場動態,法規,趨勢分析

  • 市場動態
  • 成長要素
  • 阻礙因素
  • 市場機會
  • 影響分析
  • 主要的發展
  • 技術進步
  • 法規方案

第4章 市場分析:各產品類型

  • 簡介
  • 市場佔有率分析
  • 與前一年同期比較成長分析
  • 市場區隔趨勢
  • 噴霧器
  • MDI
  • DPI

第5章 市場分析:各用途

  • 簡介
  • 市場佔有率分析
  • 與前一年同期比較成長分析
  • 市場區隔趨勢
  • 氣喘
  • COPD
  • 囊狀纖維化症

第6章 市場分析:各地區

  • 簡介
  • 市場佔有率分析
  • 與前一年同期比較成長分析
  • 市場區隔趨勢
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東
  • 非洲

第7章 競爭情形

  • 企業簡介
  • 3M Health Care
  • Allied Healthcare Products, Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim
  • CareFusion Corporation
  • GF Health Products, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Omron Healthcare, Inc.(Omron Corporation)

第8章 Section

  • 參考文件
  • 調查手法
  • 關於本公司
目錄

Title:
Pulmonary Drug Delivery Systems Market, By Product Type (Nebulizers, MDIs, DPIs), By Application (Asthma, COPD, Cystic Fibrosis), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Orally inhaled and nasal drug products (OINDPs) are the products which include metered dose (MDIs), dry powder inhalers (DPIs), nasal sprays and nebulizers. According to FDA, respiratory inhalers are classified under Class II medical devices. All inhaled products have to undergo mandatory test for extractables, leachables and microbial contaminants. Specific tests for OINDPs include aerodynamic particle size distribution (APSD) and delivered dose uniformity (DDU). These tests are regarded as key parameters for assessing performance of the OINDPs. In addition, nasal sprays and MDIs are supplemented by tests to monitor the performance of the actuator and metering valve such as plume geometry and spray pattern.

Restraints of the Global Pulmonary Drug Delivery Systems Market

Major factors hampering the growth of the pulmonary drug delivery systems market during the forecast period constitutes of stringent regulations, and complications in use.

Key features of the study:

  • This report provides in-depth analysis of the global pulmonary drug delivery systems market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019-2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global pulmonary drug delivery systems market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca plc, Boehringer Ingelheim, CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., and Philips Healthcare.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global pulmonary drug delivery systems market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Pulmonary Drug Delivery Systems Market, By Product Type:
    • Nebulizers
    • MDIs
    • DPIs
  • Global Pulmonary Drug Delivery Systems Market, By Application:
    • Asthma
    • COPD
    • Cystic Fibrosis
  • Global Pulmonary Drug Delivery Systems Market, By Geography:
    • North America
    • By Product Type
  • Nebulizers
  • MDIs
  • DPIs
    • By Application
  • Asthma
  • COPD
  • Cystic Fibrosis
    • By Country:
  • U.S.
  • Canada
    • Europe
    • By Product Type
  • Nebulizers
  • MDIs
  • DPIs
    • By Application
  • Asthma
  • COPD
  • Cystic Fibrosis
    • By Country:
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
    • Asia Pacific
    • By Product Type
  • Nebulizers
  • MDIs
  • DPIs
    • By Application
  • Asthma
  • COPD
  • Cystic Fibrosis
    • By Country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
    • Latin America
    • By Product Type
  • Nebulizers
  • MDIs
  • DPIs
    • By Application
  • Asthma
  • COPD
  • Cystic Fibrosis
    • By Country
  • Brazil
  • Argentina
  • Mexico
  • Rest of LATAM
    • Middle East:
    • By Product Type
  • Nebulizers
  • MDIs
  • DPIs
    • By Application
  • Asthma
  • COPD
  • Cystic Fibrosis
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
    • Africa
    • By Product Type
  • Nebulizers
  • MDIs
  • DPIs
    • By Application
  • Asthma
  • COPD
  • Cystic Fibrosis
    • By Country/Region:
  • Central Africa
  • South Africa
  • North Africa
  • Company Profiles
    • 3M Health Care*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments
    • Allied Healthcare Products, Inc.
    • AstraZeneca plc
    • Boehringer Ingelheim
    • CareFusion Corporation
    • GF Health Products, Inc.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Novartis AG
    • Omron Healthcare, Inc.
    • Glenmark Pharmaceuticals
    • PARI Respiratory Equipment, Inc.
    • Philips Healthcare

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
    • Market Definition and Scope
    • Executive Summary
    • Market Snippet, By Product Type
    • Market Snippet, By Application
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Technological Advancement
    • Regulatory Scenario

4. Global Pulmonary Drug Delivery Systems Market, By Product Type, 2017 - 2027 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2019-2027
    • Segment Trends
    • Nebulizers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • Segment Trends
    • MDIs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • Segment Trends
    • DPIs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • Segment Trends

5. Global Pulmonary Drug Delivery Systems Market, By Application, 2017 - 2027 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2019-2027
    • Segment Trends
    • Asthma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • Segment Trends
    • COPD
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • Segment Trends
    • Cystic Fibrosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • Segment Trends

6. Global Pulmonary Drug Delivery Systems Market, By Regions, 2017 - 2027 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2019-2027
    • Segment Trends
    • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • U.S.
    • Canada
    • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

    • Company Profiles
    • 3M Health Care
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Allied Healthcare Products, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • AstraZeneca plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Boehringer Ingelheim
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • CareFusion Corporation
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GF Health Products, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Omron Healthcare, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Other Major Players
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

    • References
    • Research Methodology
    • About us and Sales Contact